Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,649 GBX | +0.79% | +4.10% | +13.67% |
Apr. 24 | CureVac Begins Early Stage Portion of Investigational Vaccine Trial | MT |
Apr. 24 | Global markets live: Heineken, AT&T Hasbro, Visa, Boeing... |
Sales 2024 * | 31.48B 39.33B | Sales 2025 * | 33.38B 41.71B | Capitalization | 66.85B 83.53B |
---|---|---|---|---|---|
Net income 2024 * | 5.66B 7.08B | Net income 2025 * | 6.4B 7.99B | EV / Sales 2024 * | 2.51 x |
Net Debt 2024 * | 12.17B 15.2B | Net Debt 2025 * | 8.93B 11.16B | EV / Sales 2025 * | 2.27 x |
P/E ratio 2024 * |
11.8
x | P/E ratio 2025 * |
10.5
x | Employees | 70,212 |
Yield 2024 * |
3.72% | Yield 2025 * |
3.97% | Free-Float | 92.58% |
Latest transcript on GSK plc
1 day | -0.91% | ||
1 week | +2.89% | ||
Current month | -4.25% | ||
1 month | -3.01% | ||
3 months | +5.22% | ||
6 months | +11.29% | ||
Current year | +12.81% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +3.04% | - | |
2.51% | 5 M€ | +5.27% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 1,650 | +0.83% | 1 384 812 |
24-04-24 | 1,636 | -0.91% | 4,326,760 |
24-04-23 | 1,651 | +0.70% | 4,662,621 |
24-04-22 | 1,640 | +2.53% | 7,020,161 |
24-04-19 | 1,599 | +0.98% | 5,148,977 |
Delayed Quote London S.E., April 24, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.81% | 83.1B | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- GSK Stock